Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Med Hypotheses ; 157: 110719, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34717073

ABSTRACT

Venous thromboembolism (VTE) is a significant public health issue causing severe morbidity and mortality. One of the most vulnerable populations for VTE development are cancer patients. And among them, patients with brain tumors have arguably the highest risk of developing this often fatal complication. Hyperglycemia is a well-known factor which leads to a wide variety of pro-thrombotic changes. In this article, we review the current literature on the topic of VTE in brain tumor patients. We also discuss the known correlation between VTE and glycemia, as well as the importance and frequency of glycemia dysregulation in brain tumor patients. Based on the already well-known importance of glucose metabolism in cancer patients, as well as the previous research of our group, we hypothesize that there is a significant number of brain tumor patients who have chronically elevated glycemia, a fact that so-far hasn't been reported. We argue that these patients carry a significantly higher risk of VTE development and would benefit greatly from strict glycemic control. We present our hypothesis, the ways in which to test it, as well as the possible counter-arguments against it. Our hope is that other investigators will be inspired by our article to continue this type of research, since we consider the topic of VTE in brain tumor patients highly important and urgent, primarily due to its prevalence and severity.


Subject(s)
Brain Neoplasms , Venous Thromboembolism , Venous Thrombosis , Brain Neoplasms/complications , Humans , Risk Factors , Venous Thromboembolism/complications , Venous Thromboembolism/epidemiology
2.
Acta Clin Belg ; 72(6): 461-464, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28420292

ABSTRACT

Imatinib mesylate (IM), a tyrosine kinase inhibitor, is the treatment of choice in patients with chronic myeloid leukemia (CML). It is considered a very safe drug, with mostly mild and reversible side effects. Lately, it has been suggested that adverse events may occur after a long term. We report a case of a 72-year-old woman diagnosed with blastic phase of Philadelphia chromosome positive CML treated with IM for 28 months. The patient presented first with ascites as a side effect of the drug. When the ascites re-occurred, it was caused by neuroendocrine tumor (NET) with peritoneal carcinomatosis. We believe this is the first case of a NET as a secondary malignancy (SM) after IM treatment. SM have been described in patients on IM before. It is unclear whether these tumors are caused by imatinib or found more easily because of close follow-up.


Subject(s)
Antineoplastic Agents/adverse effects , Cecal Neoplasms/chemically induced , Imatinib Mesylate/adverse effects , Neoplasms, Second Primary/chemically induced , Neuroendocrine Tumors/chemically induced , Aged , Ascites/chemically induced , Female , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...